KIT Mutation

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Promyelocytic Leukemia1
KIT Mutation	Nilotinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID5573 Compared to non-treated control cells, Kasumi-1 cells (KIT-mutated cell lines) that were exposed to nilotinib (30 uM) showed a 60% reduction in colony numbers. Further evidence to support cell death i… (full text at CIViC) PMID 28720666 · Shen et al., 2017 · Open in CIViC	civic
Core Binding Factor Acute Myeloid Leukemia1
KIT Mutation	Dasatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID8576 This is a prospective clinical trial testing the safety and efficacy of adding dasatinib to chemotherapy (cytarabine-daunorubicin/HiDAC) in patients with Core Binding Factor (CBF) AML (i.e RUNX1-RUNX1… (full text at CIViC)

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Acute Promyelocytic Leukemia1

KIT Mutation

Nilotinib

Predictive

Supports Sensitivity Response

submitted

EID5573

Compared to non-treated control cells, Kasumi-1 cells (KIT-mutated cell lines) that were exposed to nilotinib (30 uM) showed a 60% reduction in colony numbers. Further evidence to support cell death i… (full text at CIViC)

PMID 28720666 · Shen et al., 2017 · Open in CIViC

civic

Core Binding Factor Acute Myeloid Leukemia1

KIT Mutation

Dasatinib

Predictive

Supports Sensitivity Response

submitted

EID8576

This is a prospective clinical trial testing the safety and efficacy of adding dasatinib to chemotherapy (cytarabine-daunorubicin/HiDAC) in patients with Core Binding Factor (CBF) AML (i.e RUNX1-RUNX1… (full text at CIViC)

Gastrointestinal Stromal Tumor5
KIT Mutation	Imatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11282 In this phase II, randomized, open-label trial, 147 patients with histologically confirmed, unresectable or metastatic gastrointestinal stromal tumour that expressed CD117 were enrolled. Patients were… (full text at CIViC) PMID 12181401 · Demetri et al., 2002 · Open in CIViC	civic
KIT Mutation	Imatinib + PictilisibCombination	Predictive	D	Supports Sensitivity Response	2	accepted	EID919 Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor effic… (full text at CIViC) PMID 23231951 · Floris et al., 2013 · Open in CIViC	civic
KIT Mutation	Regorafenib Anhydrous	Predictive	A	Supports Sensitivity Response	4	rejected	EID11283 In this phase III, randomized, placebo-controlled trial, 240 patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rand… (full text at CIViC) PMID 23177515 · Demetri et al., 2013 · Open in CIViC	civic
KIT Mutation	Ripretinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11284 In this double-blind, randomized, placebo-controlled, phase III trial, 154 patients with advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib. Th… (full text at CIViC) PMID 32511981 · Blay et al., 2020 · Open in CIViC	civic
KIT Mutation	Sunitinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11285 In this phase III, randomized, double-blind, placebo-controlled trial, 312 patients were randomized in a 2:1 ratio to receive sunitinib or placebo. Median time to tumour progression was 27.3 weeks (95… (full text at CIViC) PMID 17046465 · Demetri et al., 2006 · Open in CIViC	civic

Gastrointestinal Stromal Tumor5

KIT Mutation

Imatinib

Predictive

Supports Sensitivity Response

submitted

EID11282

In this phase II, randomized, open-label trial, 147 patients with histologically confirmed, unresectable or metastatic gastrointestinal stromal tumour that expressed CD117 were enrolled. Patients were… (full text at CIViC)

PMID 12181401 · Demetri et al., 2002 · Open in CIViC

civic

KIT Mutation

Imatinib + PictilisibCombination

Predictive

Supports Sensitivity Response

accepted

EID919

Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor effic… (full text at CIViC)

PMID 23231951 · Floris et al., 2013 · Open in CIViC

civic

KIT Mutation

Regorafenib Anhydrous

Predictive

Supports Sensitivity Response

rejected

EID11283

In this phase III, randomized, placebo-controlled trial, 240 patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rand… (full text at CIViC)

PMID 23177515 · Demetri et al., 2013 · Open in CIViC

civic

KIT Mutation

Ripretinib

Predictive

Supports Sensitivity Response

submitted

EID11284

In this double-blind, randomized, placebo-controlled, phase III trial, 154 patients with advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib. Th… (full text at CIViC)

PMID 32511981 · Blay et al., 2020 · Open in CIViC

civic

KIT Mutation

Sunitinib

Predictive

Supports Sensitivity Response

submitted

EID11285

In this phase III, randomized, double-blind, placebo-controlled trial, 312 patients were randomized in a 2:1 ratio to receive sunitinib or placebo. Median time to tumour progression was 27.3 weeks (95… (full text at CIViC)

PMID 17046465 · Demetri et al., 2006 · Open in CIViC

civic

Melanoma2
KIT Mutation	Imatinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1222 In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of … (full text at CIViC) PMID 21690468 · Guo et al., 2011 · Open in CIViC	civic
KIT Mutation	Nilotinib	Predictive	B	Supports Sensitivity Response	2	submitted	EID7145 A phase II trial assessed if nilotinib demonstrated response in a subset of 42 melanoma patients (acral and mucosal subtypes) harboring KIT gene mutations and/or amplification. Overall, 25 (59.5%) had… (full text at CIViC) PMID 26424760 · Lee et al., 2015 · Open in CIViC	civic

Melanoma2

KIT Mutation

Imatinib

Predictive

Supports Sensitivity Response

accepted

EID1222

In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of … (full text at CIViC)

PMID 21690468 · Guo et al., 2011 · Open in CIViC

civic

KIT Mutation

Nilotinib

Predictive

Supports Sensitivity Response

submitted

EID7145

A phase II trial assessed if nilotinib demonstrated response in a subset of 42 melanoma patients (acral and mucosal subtypes) harboring KIT gene mutations and/or amplification. Overall, 25 (59.5%) had… (full text at CIViC)

PMID 26424760 · Lee et al., 2015 · Open in CIViC

civic

Evidence by cancer (9 items)

Clinical significance (0)